A Phase 3 interventional study of TJO-087 and Cyclosporine ophthalmic solution 0.05% in Dry Eye Syndrome, sponsored by Taejoon Pharmaceutical Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by Taejoon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.
Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 52 interventional ones that give a count, is one of 9 that started in 2020, is one of 16 in phase 3, and was the 39th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 40+
AJU Pharm Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Nu Eyne Co., Ltd. · Sites in Korea, Republic of
Ages 19–60
Hanlim Pharm. Co., Ltd. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 17 · Phase 4 7
First in 2008; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 182 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 99 across the 52 interventional studies, 275 across the 4 observational. Of the 44 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 58 have an industry lead sponsor. The 10 most frequent:
Taejoon Pharmaceutical Co., Ltd. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Taejoon Pharmaceutical Co., Ltd. has 6 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397949Samsung Medical CenterRebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery | 2026-12 |
| NCT07656688Huons Co., Ltd.Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TJO-087
Drug: Cyclosporine ophthalmic solution 0.05%
Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
Change From Baseline in Non-anesthetic Schirmer Test at Week 32
The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac.
Time frame: Baseline and Week 32
Change From Baseline in Non-anesthetic Schirmer Test at Week 8, 16, 24
The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac.
Time frame: Baseline, Week 8, 16 and 24
Change From Baseline in Corneal Fluorescein Staining Score at Week 8, 16, 24 and 32
Change from Baseline in corneal staining of the worse eye using blue fluorescein staining procedure.
Time frame: Baseline, Week 8, 16, 24 and 32
Started Jun 2020 (actual). Primary completion is estimated for Aug 2022, 26 months after the start.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 26 months is above that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taejoon Pharmaceutical Co., Ltd. →